$ALNY News Leading stocks prove their mettle 11:53 a.m.

New Post Public Reply Private Reply Replies (0) Message Board

Dec 16, 2013 at 10:11 AM

$ALNY News

Leading stocks prove their mettle 11:53 a.m. Aug. 22, 2013 - The Trading Deck
Don't fight the tape 10:27 a.m. May 28, 2013 - The Trading Deck
SAC Capital Advisors likes this pharma stock 3:24 p.m. April 18, 2013 - Insider Monkey
Synageva director bought shares for trust 1:41 p.m. Jan. 17, 2013 - Insider Monkey
Six stocks to watch for potential up moves 11:14 a.m. Jan. 17, 2013 - The Trading Deck
S&P 500 challenges the 1,440 resistance 9:27 a.m. Sept. 13, 2012 - Michael Ashbaugh
Investing in ‘junk DNA’ 9:28 p.m. Sept. 11, 2012 - Jen Wieczner
Monsanto inks biopesticides deal with Alnylam 8:30 a.m. Aug. 28, 2012 - MarketWatch.com
12 biotech stocks hit 52-week highs 2:43 p.m. July 27, 2012 - Val Brickates Kennedy
Monday’s biggest gaining and declining stocks 2:35 p.m. July 16, 2012 - MarketWatch
Alnylam soars 31% on drug study 10:19 a.m. July 16, 2012 - Val Brickates Kennedy
Alnylam: Progress with genetic-disorder treatment 6:35 a.m. July 16, 2012 - MarketWatch.com
3 med stocks to get your heart pumping 12:53 p.m. April 5, 2012 - The Trading Deck
Stocks to watch Thursday: GM, Agilent, NetApp 6:51 a.m. Feb. 16, 2012 - MarketWatch
Alnylam climbs 16% on stock offer pricing 2:07 p.m. Feb. 15, 2012 - Val Brickates Kennedy
Stocks to watch Wednesday: Hartford, Aflac, Zynga 6:45 a.m. Feb. 15, 2012 - MarketWatch
Tuesday’s biggest gaining and declining stocks 5:47 p.m. Feb. 14, 2012 - Sue Chang
MGM, Monsanto among Tuesday upgrades 10:54 a.m. Sept. 13, 2011 - Tom Bemis
Vertex, Alnylam gain in drug-stock trading 12:22 p.m. Feb. 23, 2011 - Val Brickates Kennedy
Alnylam shares jump on analyst upgrade 9:55 a.m. Feb. 23, 2011 - Val Brickates Kennedy

Alnylam: Bold Moves Toward A New Class Of Medicine 6:33 p.m. Dec. 11, 2013 - Seeking Alpha
Isis Ally Alnylam - Trying To Understand Its Astounding Valuations 10:06 a.m. Dec. 10, 2013 - Seeking Alpha
Alnylam Presents New Pre-clinical Data on ALN-AT3 for Treatment of Hemophilia and RBD at ASH 7:59 p.m. Dec. 9, 2013 - benzinga.com
Alnylam's CEO Presents at The 25th Annual Piper Jaffray Healthcare Conference (Transcript) 4:21 p.m. Dec. 4, 2013 - Seeking Alpha
Best Biotech CEO of 2013: Your Vote Counts 8:07 a.m. Dec. 4, 2013 - TheStreet.com
Alnylam Pharmaceuticals' Management Presents at Deutsche Bank BioFEST Conference (Transcript) 2:01 p.m. Dec. 2, 2013 - Seeking Alpha
Alnylam Earns Milestone Payment - Analyst Blog 5:52 p.m. Nov. 26, 2013 - Zacks.com
Today's Stocks Driving Success For The Drugs Industry 12:04 p.m. Nov. 26, 2013 - TheStreet.com
Alnylam Earns $7M Milestone Payment from Partner Genzyme for Phase II Success with Patisiran 6:02 a.m. Nov. 25, 2013 - benzinga.com
Biotech Stock Roundup: Vanda Soars, Sarepta Slumps - Analyst Blog 11:33 a.m. Nov. 20, 2013 - Zacks.com
First Week Of ALNY January 2014 Options Trading 11:55 a.m. Nov. 19, 2013 - TheStreet.com
Alnylam Presents New Pre-clinical Data on RNAi Therapeutics at American Heart Association Meeting 3:54 p.m. Nov. 17, 2013 - benzinga.com
Alnylam Pharmaceuticals Larger Than S&P 500 Component Teradyne 4:39 p.m. Nov. 15, 2013 - TheStreet.com
Alnylam Announces Positive Phase II Data for Patisiranfor for Treatment of TTR-Mediated Amyloidosis, Initiates Phase III Trial 8:26 a.m. Nov. 10, 2013 - benzinga.com
Wider-than-Expected Q3 Loss at Alnylam - Analyst Blog 10:00 a.m. Nov. 7, 2013 - Zacks.com
10-Q: ALNYLAM PHARMACEUTICALS, INC. 8:20 a.m. Nov. 7, 2013 - Edgar Online - (EDG = 10Q, 10K)
Alnylam Pharmaceuticals' CEO Discusses Q3 2013 Results - Earnings Call Transcript 11:43 p.m. Nov. 6, 2013 - Seeking Alpha
3 Potential Game-Changers In The Biotech Industry 4:45 p.m. Nov. 5, 2013 - Seeking Alpha
Alnylam Presents New Pre-clinical Data on ALN-AAT 3:12 p.m. Nov. 2, 2013 - benzinga.com
Pipeline Progress at Alnylam - Analyst Blog 6:05 p.m. Oct. 30, 2013 - Zacks.com

Alnylam Initiates Phase II Clinical Trial with ALN-TTRsc, a Subcutaneously Delivered RNAi Therapeutic Targeting Transthyretin (TTR) in Development for the Treatment of TTR-Mediated Amyloidosis (ATTR) 8:00 a.m. Today - BusinessWire
Dividends, FDA Approved Treatments, Clinical Data Presentations and Completed License Applications - Research Report on Medtronic, Auxilium, Alnylam, Infinity, and Halozyme 8:00 a.m. Dec. 11, 2013 - PR Newswire
Alnylam Presents New Pre-clinical Data on ALN-AT3, an RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD) 7:00 p.m. Dec. 9, 2013 - BusinessWire
New Alnylam Pre-clinical Results on ALN-CC5, an RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases, Demonstrate up to 98% Serum C5 Knockdown and up to 94% Inhibition of Hemolytic Activity in Non-Human Primates 7:30 p.m. Dec. 8, 2013 - BusinessWire
Healthcare Sector Announce Awards, Conference Participation, Partnerships, and Closure of Public Offering - Research Report on Regeneron, Alnylam, Galena Biopharma, Amedisys, and Aeterna Zentaris 8:00 a.m. Dec. 3, 2013 - PR Newswire
Alnylam to Webcast Presentation at Upcoming Investor Conferences 4:00 p.m. Nov. 25, 2013 - BusinessWire
Upcoming Webinars, FDA Clearances, Preclinical Data Presentations, Completed Acquisitions and Financial Results - Research Report on Teva, Boston Scientific, Alnylam, Wright Medical, and Onconova 8:00 a.m. Nov. 25, 2013 - PR Newswire
Alnylam Earns $7 Million Milestone Payment from Genzyme for Phase II Success with Patisiran (ALN-TTR02), an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR) 7:00 a.m. Nov. 25, 2013 - BusinessWire
Alnylam Presents New Pre-clinical Data on RNAi Therapeutics for Cardiovascular Disease at American Heart Association Meeting 4:00 p.m. Nov. 17, 2013 - BusinessWire
Healthcare Sector Announced Financial Results and Recognition - Research Report on Alnylam Pharmaceuticals, Opko, Enzymotec, Cambrex, and XOMA 8:00 a.m. Nov. 15, 2013 - PR Newswire
RXi Pharmaceuticals' Valuation Moves From Product To Platform 10:19 a.m. Nov. 12, 2013 - ACCESSWIRE
Alnylam Receives Fast Track Designation for Patisiran (ALN-TTR02), an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR) 7:00 a.m. Nov. 11, 2013 - BusinessWire
Tekmira's Partner Initiates Phase III Trial With LNP-Enabled Patisiran (ALN-TTR02) 11:28 p.m. Nov. 10, 2013 - GlobeNewswire
Clinical Trial Initiations, Conferences Participations, Strategic Collaborations, and Presentation of New Pre-Clinical Data - Research Report on Biogen Idec, BioMarin, Medivation, Cytori, and Alnylam 8:00 a.m. Nov. 8, 2013 - PR Newswire
Alnylam to Present New Pre-clinical Data on Multiple RNAi Therapeutic Programs at 55th Annual Meeting of the American Society of Hematology (ASH) 9:00 a.m. Nov. 7, 2013 - BusinessWire
Alnylam Pharmaceuticals Reports Third Quarter 2013 Financial Results 4:00 p.m. Nov. 6, 2013 - BusinessWire
Alnylam Presents New Pre-clinical Data on ALN-AAT, an RNAi Therapeutic Targeting Alpha-1-Antitrypsin (AAT) for the Treatment of AAT Deficiency Liver Disease 2:00 p.m. Nov. 2, 2013 - BusinessWire
Acquisitions, Financial Results, Clinical Trial Applications, and Upcoming Earnings Schedules - Research Report on Illumina, DENTSPLY, Alnylam, Sirona, and Santarus 9:00 a.m. Nov. 1, 2013 - PR Newswire
Alnylam to Webcast Conference Call Discussing Third Quarter 2013 Financial Results 4:00 p.m. Oct. 30, 2013 - BusinessWire
Alnylam Files Clinical Trial Application to Initiate a Phase I Study for ALN-AT3, a Subcutaneously Administered RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia A and B 8:00 a.m. Oct. 29, 2013 - BusinessWire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CVS Health Under Fire: Fiduciary Duty Breach?

CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...

Cut Winter Heating Costs with Townsend's Rebate Help

Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...

HONA Faces Legal Heat: Investor Lawsuit Over Losses

The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...

Farm Aid 2026: A Resilient Tribute to Family Farmers

Shining a Light on Essential Family Farmers Every year, thousands gather for Farm Aid to back the unsung heroes who put food on our plates. In 2026, the scene shifted to the amphitheater at Virginia Beach, where an epic lineup of music took stage not just to entertain but to underline a critical issue—family farmers are fighting for survival. These folks aren't merely...

Timur Turlov Leads FIDE with Chess and Digital Focus

An Unpredicted Victory in Samarkand Well, color me surprised. Timur Turlov's made waves by clinching the role of FIDE President at the General Assembly in Samarkand. This one's quite the turn for the chess world—Kazakhstan’s own stepping up to run the whole show. This isn't just some ceremonial post either. Turlov, who's been pulling strings over at the Kazakhstan...

Krispy Kreme Faces Legal Probe: Fiduciary Breach?

Diving Deep into the Krispy Kreme Allegations Look, this isn't your run-of-the-mill donut drama. When you hear rumblings of corporate missteps, especially ones that involve potential breaches of fiduciary duties, it's time to perk up those ears. Over at Krispy Kreme, Inc. (NASDAQ:DNUT), there's some heat in the kitchen, and it's not just from frying those glazed beauties....

Endurance Energy's Modular Tech Revs Up Southeast Asia

Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...

Quay Sunglasses: Luxury Looks, Affordable Prices

Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...

AI and Storytelling Make Waves in Science Education

University's Innovative Approach to Learning Alright, here's something you don't see every day. The University of Phoenix managed to snag some kudos from an academic journal for using AI and storytelling to teach environmental science. That's like hitting two bulls-eyes with one shot in the world of education. The recognition from Glacies for this Editor's Choice paper...

China Southern Airlines Marks 70th Anniversary in NYC

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...